Comparable real-world effectiveness between switches to cabotegravir + rilpivirine long-acting or modern daily oral regimens in the United States: an OPERA cohort study.

ABSTRACT:

Introduction

Cabotegravir + rilpivirine long-acting (CAB+RPV LA) injectable was approved in the United States in 2021 for HIV-1 treatment in virologically suppressed (viral load [VL] <50 copies/mI individuals. In clinical trials, CAB+RPV LA was non-inferior to oral antiretroviral therapy (ART) regimens in virologically suppressed individuals. We compared real-world effectiveness between CAB+RPV LA and oral ART regimens and assessed predictors of confirmed virologic failure (CVF) on CAB+RPV LA.

Methods

From the OPERA^® cohort, ART-experienced, virologically suppressed adults with HIV switching to CAB+RPV LA or a new oral ART regimen between 21 January 2021 and 31 December 2022 were followed through 30 June 2023. CVF was defined as 2 VL ≥200 copies/ml or 1 VL ≥200 co

SUBMITTER: Hsu RK 

PROVIDER: S-EPMC12710068 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature